Get to know our Pipeline

Learn More About our Technology​

Platform 1 A
Preventing antigen escape

Bispecific Chimeric Antigen Receptor (CAR) T cells are designed to address antigen escape

Platform 2
Targeting immunosuppressive microenvironment

TGF-β CAR rewires T cell responses to soluble factors to overcome the immune suppressive microenvironment in cancer

Platform 1 A
Preventing antigen escape

Bispecific Chimeric Antigen Receptor (CAR) T cells are designed to address antigen escape

Platform 1 B
Curing autoimmune disease

Bispecific Chimeric Antigen Receptor (CAR) T cells are designed to address autoimmunity

Platform 1 B
Curing autoimmune disease

Bispecific Chimeric Antigen Receptor (CAR) T cells are designed to address autoimmunity

Platform 3
Distinguishing cancer cells from normal cells

iCAR technology allows specific killing of cancer cells while sparing normal tissue, with potential to treat all solid tumors

Platform 2
Targeting immunosuppressive microenvironment

TGF-β CAR rewires T cell responses to soluble factors to overcome the immune suppressive microenvironment in cancer.

Platform 3
Distinguishing cancer cells from normal cells

iCAR technology allows specific killing of cancer cells while sparing normal tissue, with potential to treat all solid tumors.

You are about to leave Immpact Bio's website to an external website.

Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.

You are about to leave Immpact Bio's website to an external website.

Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.

You are about to leave Immpact Bio's website to an external website.

Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.

You are about to leave Immpact Bio's website to an external website.

Immpact Bio is not responsible for the accuracy or content of information contained on external/third-party websites.